ImmunoPrecise Antibodies Ltd (OTCMKTS:IPATF) (CVE:IPA) said Thursday it has opened a new office in Cambridge, Massachusetts.
The office will be staffed at first for sales and business development and will take advantage of the Cambridge area’s focus on biotech and pharmaceuticals.
READ: Immunoprecise Antibodies reports 2Q revenue doubled on increased capacity, European expansion
“Establishing a base in the Boston/ Cambridge area, a powerhouse for biotech and pharma, is a strategic next step for ImmunoPrecise. We already have a strong base of both European and US clients, and this move will help us enhance and grow our Boston area business and relationships,” said Jennifer Bath, CEO of ImmunoPrecise, in a statement.
Based in Victoria, British Columbia, ImmunoPrecise is a Canadian contract research organization focused on antibody discovery and manufacturing.
ImmunoPrecise shares slipped 1.67% to hit C$0.59 in morning trade on Thursday.
Contact Ellen Kelleher at ellen@proactiveinvestors.com